The Neuroscience of Being Human

The Neuroscience of Synthetic Cannabinoids

How full agonism at the CB1 receptor produces effects that cannabis never could, why the absence of CBD buffering makes these compounds uniquely dangerous, and what mass casualty events reveal about the pharmacology of an unregulated market

1,540-word article with 8 Harvard references.

Full agonism: why these are not cannabis

The distinction between a partial agonist and a full agonist is not academic. It is the difference between a drug that has a ceiling effect and a drug that does not. THC, the principal psychoactive component of cannabis, is a partial agonist at the CB1 cannabinoid receptor. At low doses, it activates the receptor proportionally to the dose. At higher doses, its ability to further activate the receptor reaches a plateau. There is a pharmacological ceiling above which more THC does not produce more CB1 activation. Synthetic cannabinoids are full agonists. They can activate the CB1 receptor to its maximum capacity. There is no ceiling. More drug produces more activation until the receptor system is overwhelmed (Castaneto et al., 2014).

Fantegrossi et al. (2014) documented the consequences of this pharmacological difference. Full CB1 agonism at high receptor occupancy produces effects that partial agonism cannot generate regardless of dose: generalised seizures, profound hypothermia or hyperthermia, catatonic states, cardiovascular collapse, and acute kidney injury. These are not exaggerated versions of cannabis intoxication. They are qualitatively different clinical syndromes that emerge from a level of CB1 activation that THC is pharmacologically incapable of producing. The additional absence of CBD, which in natural cannabis acts as a negative allosteric modulator at CB1 and partially restrains THC's effects, means that synthetic cannabinoid users receive full agonism without any endogenous buffering. The metaphor is a car with a more powerful engine and no brakes.

Potency, binding affinity, and the problem of unknown compounds

The first generation of synthetic cannabinoids, developed by John W. Huffman for research purposes and designated with the JWH prefix, had binding affinities at CB1 in the same general range as THC, roughly two to ten times higher. The compounds that have subsequently appeared on the market bear no such restraint. Adams et al. (2017), documenting the AMB-FUBINACA mass casualty event in New York in which thirty-three people collapsed simultaneously in a public park, reported that this compound has a CB1 binding affinity approximately eighty-five times greater than THC. The clinical presentations included unresponsiveness, slow mechanical breathing, blank staring, and an appearance so consistent with the fictional undead that media reports described the scene as a zombie outbreak. The compound was active at microgram doses, sprayed unevenly onto dried plant material, meaning that one portion of the product might contain a barely active dose while the adjacent portion contained a dose sufficient to produce coma.

Trecki et al. (2015), writing in the New England Journal of Medicine, documented the broader pattern: clusters of synthetic cannabinoid-related illnesses and deaths appearing across the United States, caused by compounds that varied from batch to batch and sometimes from packet to packet within the same batch. The problem is structural. The market responds to scheduling by substituting novel compounds. Manufacturers synthesise analogues that are technically legal because they have not yet been specifically prohibited, often without any preclinical data on their pharmacology, metabolism, or toxicity. The user purchasing a product labelled as herbal incense or potpourri has no way of knowing whether they are about to consume a compound with ten times the potency of THC or one hundred times the potency, whether the compound has been sprayed evenly or has pooled in one corner of the packet, or whether the compound has active metabolites that prolong or intensify its effects.

Clinical toxicology: what emergency departments see

Hermanns-Clausen et al. (2013) published one of the first case series in which the synthetic cannabinoid consumed was analytically confirmed through toxicological testing, eliminating the ambiguity that plagued earlier reports. The clinical presentations included seizures in patients with no seizure history, acute psychosis with paranoid delusions and visual hallucinations, tachycardia exceeding one hundred and fifty beats per minute, hypertension, chest pain, and agitation requiring physical restraint and sedation. Several patients required intubation. The presentations were consistent across cases and distinct from cannabis intoxication, which does not produce seizures, rarely produces psychosis requiring hospitalisation, and does not cause the cardiovascular emergencies documented in these cases.

Spaderna et al. (2013) reviewed the clinical toxicology literature and documented additional complications including acute kidney injury, rhabdomyolysis, myocardial infarction in young users, and deaths. The cardiovascular toxicity reflects the widespread distribution of CB1 receptors in the cardiovascular system, where full agonism produces effects including coronary vasospasm, arrhythmia, and myocardial ischaemia that partial agonism by THC does not typically produce. The psychosis risk is particularly concerning because it can persist beyond the acute intoxication period. Cases of prolonged psychotic episodes lasting days to weeks after synthetic cannabinoid use have been documented, suggesting that full CB1 agonism may trigger persistent psychiatric syndromes in vulnerable individuals, a pattern not commonly observed with natural cannabis at typical doses.

Dependence and withdrawal

Cannabis produces a withdrawal syndrome that is real but generally mild: irritability, sleep disturbance, decreased appetite, and restlessness. Synthetic cannabinoids produce a withdrawal syndrome that is substantially more severe. Castaneto et al. (2014) documented reports of withdrawal including intense craving, profuse sweating, nausea, vomiting, diarrhoea, tachycardia, hypertension, and seizures. The greater severity reflects the greater degree of CB1 receptor adaptation produced by full agonism compared to partial agonism. A receptor system that has been chronically activated to its maximum capacity downregulates more profoundly than one that has been partially activated, and the withdrawal state that emerges when that adapted system is suddenly deprived of the full agonist is correspondingly more severe.

Schifano et al. (2015), reviewing synthetic cannabinoids in the context of the broader novel psychoactive substances landscape, noted that dependence develops rapidly in regular users, with daily use becoming established within weeks. The user populations most affected include homeless individuals, prison populations, and individuals with pre-existing mental health conditions, groups who are attracted to synthetic cannabinoids by their low cost, their availability in environments where other drugs are harder to obtain, and in some cases their undetectability in standard drug screening. The concentration of use in vulnerable populations means that the most severe consequences fall on the people least equipped to access treatment and least likely to be accurately diagnosed when they present to emergency departments.

The regulatory arms race

The synthetic cannabinoid market operates through a mechanism that drug policy was not designed to address. Traditional drug scheduling prohibits specific molecules. The synthetic cannabinoid market responds to each scheduling action by modifying the molecular structure to produce a novel compound that is technically legal. The modifications are often minor, a fluorine atom moved to a different position on the aromatic ring, a pentyl chain shortened to a butyl chain, but they can produce unpredictable changes in potency, receptor selectivity, metabolic profile, and toxicity. Each new compound reaches the market without any preclinical testing, without any human pharmacological data, and without any quality control. The user is the first human being to consume the compound at that dose.

Winstock and Barratt (2013), analysing Global Drug Survey data from more than fourteen thousand respondents who had used both natural and synthetic cannabis, documented the consequence of this unregulated pharmacology. Synthetic cannabinoid users were approximately thirty times more likely to seek emergency medical treatment. They reported higher rates of paranoia, psychosis, loss of consciousness, and hangover effects. The risk profile was not merely elevated. It was qualitatively different from natural cannabis, reflecting the fundamental pharmacological distinction between partial and full agonism, between buffered and unbuffered CB1 activation, and between products of known botanical composition and products of unknown chemical identity.